COM:C4THERAPEUTICS
C4 Therapeutics
- Stock
Last Close
4.01
22/11 21:00
Market Cap
344.03M
Beta: -
Volume Today
1.36M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | -30.48M - | -30.48M 0% | |||||
average payables | 3.27M - | 5.53M 69.26% | 5.09M 7.94% | 2.84M 44.27% | 1.31M 53.89% | ||
average receivables | 45.53M - | 4.55M 90.00% | 5.10M 12.00% | 3.59M 29.52% | 6.64M 84.62% | ||
book value per share | -5.39 - | -81.61 1,413.32% | 24.70 130.26% | 8.46 65.73% | 5.92 30.05% | 0.00 99.92% | |
capex per share | -0.18 - | -0.98 440.76% | -0.06 94.19% | -0.03 51.48% | -0.11 305.55% | -0.00 99.97% | |
capex to depreciation | -2.11 - | -0.85 59.96% | -0.40 52.47% | -0.86 112.92% | -3.28 283.13% | -0.91 72.30% | |
capex to operating cash flow | 0.16 - | -0.02 115.32% | 0.01 139.85% | 0.01 51.92% | 0.05 253.30% | 0.02 69.18% | |
capex to revenue | -0.14 - | -0.06 54.57% | -0.02 68.96% | -0.03 42.44% | -0.18 533.69% | ||
cash per share | 2.46 - | 66.00 2,588.02% | 32.69 50.47% | 6.72 79.45% | 5.65 15.86% | 0.01 99.91% | |
days of inventory on hand | |||||||
days payables outstanding | |||||||
days sales outstanding | 1.63K - | 78.92 95.16% | 49.30 37.53% | 45.57 7.58% | 17.29 62.06% | ||
debt to assets | 0.10 - | 0.12 17.60% | 0.06 50.73% | 0.08 47.72% | 0.20 139.07% | 0.19 6.79% | |
debt to equity | -0.18 - | -0.12 32.38% | 0.08 166.47% | 0.11 34.83% | 0.30 173.78% | 0.29 4.29% | |
dividend yield | |||||||
earnings yield | -0.04 - | -0.98 2,239.51% | -0.18 81.94% | -0.06 67.04% | -0.44 656.12% | -0.00 99.89% | |
enterprise value | 355.12M - | -41.83M 111.78% | 217.89M 620.90% | 1.45B 565.15% | 345.68M 76.15% | 280.41B 81,018.88% | |
enterprise value over ebitda | -23.49 - | 1.24 105.26% | -3.73 401.78% | -18.06 384.34% | -2.74 84.80% | -2.02K 73,391.91% | |
ev to operating cash flow | -20.91 - | -0.75 96.40% | -3.24 330.77% | -16.67 414.35% | -3.26 80.42% | -2.62K 80,336.30% | |
ev to sales | 18.34 - | -1.96 110.67% | 6.56 435.51% | 31.65 382.24% | 11.12 64.88% | ||
free cash flow per share | -1.33 - | 39.55 3,073.74% | -5.97 115.10% | -1.92 67.91% | -2.28 19.00% | -0.00 99.90% | |
free cash flow yield | -0.05 - | 1.55 3,073.74% | -0.18 111.62% | -0.06 66.98% | -0.39 549.43% | -0.00 99.90% | |
graham net net | -8.46 - | -99.28 1,073.61% | 22.49 122.65% | 4.27 81.03% | 2.15 49.54% | 0.00 99.88% | |
graham number | 11.35 - | 213.64 1,781.60% | 56.94 73.35% | 18.86 66.87% | 18.57 1.55% | 0.02 99.91% | |
income quality | 1.08 - | -1.63 250.90% | 1.01 162.16% | 1.04 2.25% | 0.83 20.27% | 0.81 2.44% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -49.19 - | -38.29 22.15% | -58.45 52.66% | 101.26 273.23% | |||
interest debt per share | 0.98 - | 10.02 923.36% | 2.12 78.81% | 0.98 53.96% | 1.83 87.03% | 0.00 99.92% | |
inventory turnover | |||||||
invested capital | -0.18 - | -0.12 32.38% | 0.08 166.47% | 0.11 34.83% | 0.30 173.78% | 0.29 4.29% | |
market cap | 376.95M - | 34.97M 90.72% | 376.70M 977.21% | 1.48B 293.56% | 288.28M 80.55% | 280.47B 97,189.14% | |
net current asset value | -102.71M - | -133.46M 29.93% | 261.66M 296.07% | 208.53M 20.31% | 145.95M 30.01% | 140.85M 3.49% | |
net debt to ebitda | 1.44 - | 2.27 57.08% | 2.72 19.80% | 0.41 84.76% | -0.46 210.01% | 0.40 187.78% | |
net income per share | -1.06 - | -24.86 2,239.51% | -5.83 76.53% | -1.87 67.97% | -2.59 38.54% | -0.00 99.90% | |
operating cash flow per share | -1.15 - | 40.54 3,630.27% | -5.91 114.59% | -1.89 68.06% | -2.17 14.79% | -0.00 99.90% | |
payables turnover | |||||||
receivables turnover | 0.22 - | 4.62 1,964.49% | 7.40 60.07% | 8.01 8.20% | 21.11 163.55% | ||
research and ddevelopement to revenue | 1.48 - | 2.25 52.23% | 2.36 5.13% | 2.07 12.50% | 3.79 83.28% | ||
return on tangible assets | -0.11 - | -0.29 168.85% | -0.17 42.51% | -0.17 2.41% | -0.29 72.94% | -0.35 19.87% | |
revenue per share | 1.31 - | 15.58 1,090.20% | 2.92 81.27% | 0.99 65.94% | 0.64 36.00% | ||
roe | 0.20 - | 0.30 54.59% | -0.24 177.57% | -0.22 6.52% | -0.44 98.05% | -0.54 23.09% | |
roic | 0.34 - | 0.43 27.69% | -0.19 144.00% | -0.18 4.15% | -0.28 55.98% | -0.35 25.45% | |
sales general and administrative to revenue | 0.37 - | 0.41 10.97% | 0.46 11.61% | 0.73 58.58% | 1.38 89.46% | ||
shareholders equity per share | -5.39 - | -81.61 1,413.32% | 24.70 130.26% | 8.46 65.73% | 5.92 30.05% | 0.00 99.92% | |
stock based compensation to revenue | 0.03 - | 0.08 155.52% | 0.10 34.63% | 0.47 354.45% | 0.97 105.44% | ||
tangible asset value | -79.75M - | -111.96M 40.39% | 280.79M 350.79% | 389.61M 38.75% | 289.23M 25.76% | 246.11M 14.91% | |
tangible book value per share | -5.39 - | -81.61 1,413.32% | 24.70 130.26% | 8.46 65.73% | 5.92 30.05% | 0.00 99.92% | |
working capital | 99.58M - | 63.13M 36.61% | 337.16M 434.10% | 274.44M 18.60% | 243.01M 11.45% | 228.42M 6.00% |
All numbers in USD (except ratios and percentages)